Profile
Sector:
HealthcareIndustry:
BiotechnologyCountry:
SwitzerlandIPO:
23 September 2016Website:
http://www.acimmune.comNext earnings report:
17 July 2024Last dividends:
N/ANext dividends:
N/APrice
after hours | Fri, 28 Jun 2024 20:45:54 GMTDividend
Analysts recommendations
Institutional Ownership
ACIU Latest News
AC Immune S.A. saw its shares surge by over 50% in premarket trading on Monday following the announcement of a licensing agreement with Takeda Pharmaceutical Co. for an experimental Alzheimer's disease vaccine.
AC Immune stock is rising on Monday following the release of its first quarter 2024 earnings report, which includes details of a new collaboration with Takeda Pharmaceutical.
The heavy selling pressure might have exhausted for AC Immune (ACIU) as it is technically in oversold territory now. In addition to this technical measure, strong agreement among Wall Street analysts in revising earnings estimates higher indicates that the stock is ripe for a trend reversal.
Anavex Life Sciences (AVXL), Peakstone Realty Trust (PKST), AC Immune (ACIU), Getaround (GETR) and Akoya Biosciences (AKYA) could be solid picks to play the January Effect.
AC Immune (ACIU) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
The approval of the breakthrough treatment Leqembi for Alzheimer's Disease has put this space in the spotlight. Companies like ACIU, VAXX and PRTA are in focus, given their experimental vaccines.
Here, we discuss some reasons why investing in AC Immune (ACIU) stock now may turn out to be a prudent move.
Undeniably, the concept of growth penny stocks represent one of the hottest topics on Wall Street. And this interest goes well beyond the meme-stock phenomenon that characterized much of the market action during the post-pandemic period.
Here is how AC Immune (ACIU) and Exact Sciences (EXAS) have performed compared to their sector so far this year.
Here is how AC Immune (ACIU) and Brainsway Ltd. Sponsored ADR (BWAY) have performed compared to their sector so far this year.
What type of business is AC Immune SA?
AC Immune SA, a clinical stage biopharmaceutical company, discovers, designs, and develops medicines and diagnostic products for the prevention and treatment of neurodegenerative diseases associated with protein misfolding. Its SupraAntigen and Morphomer platforms are designed to generate vaccines, antibodies, and small molecules, which selectively interact with misfolded proteins that are common in a range of neurodegenerative diseases. The company is developing Crenezumab, a humanized, conformation-specific monoclonal antibody, which is in Phase II clinical prevention trial for the treatment of Alzheimer's disease (AD). It is also developing ACI-24, an anti-Abeta vaccine candidate that is in Phase II clinical study for AD, as well as completed Phase Ib clinical study for Down syndrome; ACI-35, an anti-Tau vaccine candidate that has completed Phase Ib clinical study; and Tau- positron emission tomography (PET) imaging tracer, which is in Phase II clinical study. In addition, the company is researching and developing small molecule Tau aggregation inhibitors for AD and NeuroOrphan indications. Further, it has discovery and preclinical stage molecules targeting range of neurodegenerative diseases, which include diagnostics targeting TDP-43, alpha-synuclein, and NLRP3. AC Immune SA has license agreements and collaborations with Genentech, Inc.; Biogen International GmbH; Janssen Pharmaceuticals, Inc.; Life Molecular Imaging SA; Eli Lilly and Company; and WuXi Biologics. The company was incorporated in 2003 and is headquartered in Lausanne, Switzerland.
What sector is AC Immune SA in?
AC Immune SA is in the Healthcare sector
What industry is AC Immune SA in?
AC Immune SA is in the Biotechnology industry
What country is AC Immune SA from?
AC Immune SA is headquartered in Switzerland
When did AC Immune SA go public?
AC Immune SA initial public offering (IPO) was on 23 September 2016
What is AC Immune SA website?
https://www.acimmune.com
Is AC Immune SA in the S&P 500?
No, AC Immune SA is not included in the S&P 500 index
Is AC Immune SA in the NASDAQ 100?
No, AC Immune SA is not included in the NASDAQ 100 index
Is AC Immune SA in the Dow Jones?
No, AC Immune SA is not included in the Dow Jones index
When does AC Immune SA report earnings?
The next expected earnings date for AC Immune SA is 17 July 2024